Fulcrum Therapeutics
FULC
119 hedge funds and large institutions have $243M invested in Fulcrum Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 33 closing their positions.
2,399% more call options, than puts
Call options by funds: $5.45M | Put options by funds: $218K
24% more capital invested
Capital invested by funds: $196M → $243M (+$47M)
7.89% more ownership
Funds ownership: 88.01% → 95.9% (+7.9%)
8% less funds holding
Funds holding: 130 → 119 (-11)
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
27% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 33
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$7.95M |
| 2 |
Morgan Stanley
New York
|
+$4.36M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.69M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.73M |
| 5 |
EAM
Exome Asset Management
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$8.37M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.03M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$3.82M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.75M |
| 5 |
BlackRock
New York
|
-$1.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$18 | +5 | +100% |
|
FULC Hedge Fund Activity: Q4 2024 in Review
119 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2024, worth a combined $243M — up 24% from $196M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of FULC and 24 opened new positions — a net loss of 9 holders — while 40 trimmed existing stakes and 33 added.
The largest buyer was Suvretta Capital Management, adding an estimated $7.95M. The largest seller was TRV GP IV, exiting entirely with an estimated $8.37M sold.
- 119 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2024, down from 130 in Q3 2024.
- Funds reported $243M of Fulcrum Therapeutics stock for Q4 2024, up 24% quarter-over-quarter.
- 24 funds opened new Fulcrum Therapeutics positions in Q4 2024 and 33 closed out, a net change of -9 holders.
- The largest Fulcrum Therapeutics buyer in Q4 2024 was Suvretta Capital Management, an estimated $7.95M added.
- The largest Fulcrum Therapeutics seller in Q4 2024 was TRV GP IV, an estimated $8.37M sold.
Based on aggregated 13F filings for Q4 2024.